TMIST is a breast cancer screening trial of nearly 165,000 women that is set to open in mid-2017. It is the first randomized trial in the world to compare two standard methods of mammography over several years to help women and their doctors decide the best ways to screen for breast cancer in the future, considering their own individual risk factors for developing the disease. TMIST will enroll asymptomatic women in the US and Canada, between the ages of 45 and 74, to compare the incidence of advanced cancers in those screened for four years with digital breast tomosynthesis vs. standard digital mammography. The study aims to provide a modern basis for the continued use of mammography for breast cancer screening. TMIST is funded by the National Cancer Institute (NCI).
Physician and Research Staff Educational Materials:
These materials are intended for promotional use among health care professionals and are NOT intended for use as patient educational materials.
Patient Educational Materials:
Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material. For sites utilizing local IRBs, please submit this in accordance with your local IRB policies prior to use.